Biotech · Private company · Morrisville, NC, US
Inhalon Biopharma, Inc.
Track this companyFree. Adds Inhalon Biopharma, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards10
- IND-enabling development for IN-005, an inhaled muco-trapping mAb therapy against Influenza AFiscal year 2025 · $1MNIH RePORTER 1R44AI188967-01A1 · fetched Nov 12, 2026
- Development of IN-003PI as passive immunization against human metapneumovirus infectionFiscal year 2025 · $1MNIH RePORTER 1R44AI191921-01A1 · fetched Nov 12, 2026
- SBIR: IND-enabling development of IN-007, an inhaled muco-trapping immunotherapy for COVID19 and other ACE2-targeted infectionsFiscal year 2025 · $1MNIH RePORTER 5R44AI177199-02 · fetched Nov 12, 2026
- IND-enabling development for IN-003, an inhaled mAb therapy against human metapneumovirus infectionFiscal year 2025 · $1MNIH RePORTER 5R44AI181347-02 · fetched Nov 12, 2026
- Pharmacokinetics analysis from first-in-human study of IN-002, a potent inhaled muco-trapping antibody therapy for RSVFiscal year 2025 · $1MNIH RePORTER 5R44AI186834-02 · fetched Nov 12, 2026
- GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial VirusFiscal year 2025 · $608.8KNIH RePORTER 5SB1AI179368-03 · fetched Nov 12, 2026
- SBIR: IND-enabling development of IN-007, an inhaled muco-trapping immunotherapy for COVID19 and other ACE2-targeted infectionsFiscal year 2024 · $1MNIH RePORTER 1R44AI177199-01A1 · fetched Nov 12, 2026
- IND-enabling development for IN-003, an inhaled mAb therapy against human metapneumovirus infectionFiscal year 2024 · $1MNIH RePORTER 1R44AI181347-01A1 · fetched Nov 12, 2026
- Pharmacokinetics analysis from first-in-human study of IN-002, a potent inhaled muco-trapping antibody therapy for RSVFiscal year 2024 · $1MNIH RePORTER 1R44AI186834-01 · fetched Nov 12, 2026
- GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial VirusFiscal year 2024 · $996.8KNIH RePORTER 5SB1AI179368-02 · fetched Nov 12, 2026